Loading...
Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to Date
Over the last 18 months, 3 immunotherapy combination regimens (ipilimumab + nivolumab, pembrolizumab + axitinib, and axitinib + avelumab) were approved by the US Food and Drug Administration for the first-line treatment of metastatic renal cell carcinoma (mRCC), making selection of the optimal first...
Saved in:
| Published in: | Cancer Manag Res |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Dove
2020
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7443011/ https://ncbi.nlm.nih.gov/pubmed/32884346 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S216605 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|